• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by TriSalus Life Sciences Inc.

    5/8/25 4:19:26 PM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001826667
    MedTech Acquisition Corp
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    TriSalus Life Sciences, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
       Over Five Years Ago
    X Within Last Five Years (Specify Year) 2020
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    TriSalus Life Sciences, Inc.
    Street Address 1 Street Address 2
    6272 WEST 91ST AVENUE
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    WESTMINSTER COLORADO 80031 415 336 8917

    3. Related Persons

    Last Name First Name Middle Name
    Murphy Sean
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Szela Mary
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Young James
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Valle William F.
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Desai Arjun
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    von Eschenbach Andrew
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hicks Kerry
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gordon Gary
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cox Brian
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Matlin David J.
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Wahlstrom Mats
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Marshak Richard
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Stevens Jennifer
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Devlin Jodi
    Street Address 1 Street Address 2
    6272 W 91st Ave
    City State/Province/Country ZIP/PostalCode
    Westminster COLORADO 80031
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-05-02    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $22,000,000 USD
    or    Indefinite
    Total Amount Sold $22,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    24

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    TriSalus Life Sciences, Inc. /s/ James Young James Young Chief Financial Officer 2025-05-08

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $TLSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results

      Funding Anticipated to Accelerate Applications Already in Use and New Additional Potential Applications Anticipated Preferred Stock Exchange to Simplify Capital Structure Private Placement Expected to Fund Business to Profitability Healthcare Focused Long-term Investors Support Strategic Vision TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and techn

      4/30/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

      Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv

      3/27/25 7:30:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping

      TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, announced today that the Centers for Medicare & Medicaid Services (CMS) has established a new Level II HCPCS code for the TriNav® Infusion System, effective April 1, 2025. This new code, C8004, provides reimbursement clarity for simulation angiograms—commonly known as mapping procedures—conducted prior to transarterial radioembolization (TARE). The introduction of C8004 provides validation of TriNav's growing role in pre-treatment ma

      3/26/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/6/25 6:09:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/31/25 5:54:39 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:15:05 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Financials

    Live finance-specific insights

    See more
    • TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update

      Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods Gross Margin of 85% and 86% for Q4 and Full-Year 2024 Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025 Management to host earnings conference call on March 27 at 8:00 a.m. EDT TriSalus Life Sciences Inc., (NASDAQ:TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our inv

      3/27/25 7:30:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call

      Q4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023 Q4 Operating Cash Flow of approximately ($5.6) million is a notable improvement compared to ($10.8) million in Q3 Company expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of 2025 Call Scheduled for Thursday, March 27, 2025, at 8:00 a.m. ET TriSalus Life Sciences® Inc. (NASDAQ:TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call. Preliminary

      1/23/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Reports Q3 2024 Financial Results and Provides Business Update

      – Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da

      11/14/24 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      12/4/24 4:00:06 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      10/21/24 8:25:05 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on TriSalus Life Sciences

      Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

      2/13/25 8:48:50 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

      12/17/24 8:31:30 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

      ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

      11/11/24 7:48:55 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Manuf, Strategy&Bus Dev. Murphy Sean was granted 15,817 shares, increasing direct ownership by 25% to 79,105 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:54:19 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • Chief Financial Officer Young James Emmett was granted 14,762 shares, increasing direct ownership by 68% to 36,488 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:49:46 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CHIEF REGULATORY OFFICER Stevens Jennifer was granted 14,481 shares, increasing direct ownership by 33% to 57,889 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/19/25 5:48:02 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    SEC Filings

    See more
    • SEC Form D filed by TriSalus Life Sciences Inc.

      D - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/8/25 4:19:26 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by TriSalus Life Sciences Inc.

      EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      5/5/25 12:15:25 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by TriSalus Life Sciences Inc.

      DEF 14A - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      4/30/25 5:21:24 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Leadership Updates

    Live Leadership Updates

    See more
    • TriSalus Life Sciences Announces Key Appointments to Board of Directors

      HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga

      2/3/25 4:05:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Announces Leadership Changes

      James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp

      1/8/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

      TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other

      9/26/24 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care